Joshua Meeks
@JoshMeeks
Followers
4K
Following
15K
Media
311
Statuses
2K
Urologic Oncologist and Scientist at Northwestern University K-index:3.7
Chicago
Joined July 2009
Physician experiences with TAR-200 in high-risk nonmuscle invasive #BladderCancer: A qualitative study of the #SunRISetrial investigators. Presentation by @JoshMeeks @NUFeinbergMed. #SUO25 written coverage by @RKSayyid @UAUrology > https://t.co/2hCcKTLr1M
@UroOnc #NMIBC
2
6
13
We continue to see ADCs and ICI move in earlier lines (including the approval in MIBC today). Here is what we touched on and have in NMIBC right now w/ @shilpaonc and & @JoshMeeks ✅ BCG ✅ BCG + IO ✅ IO ✅ TAR200 ✅Anktiva/N803 #BladderCancer #OncTwitter @OncoAlert
In our “Challenging Cases” 🗣️ on non-muscle invasive bladder cancer w/ @shilpaonc & @JoshMeeks we touched on: ✅ BCG, BCG + IO, IO alone ✅ MultiD/MedOnc role early on Full discussion: ⭐️ https://t.co/sY7M5MgZRG ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates
1
23
68
RT @OncBrothers: PeriOP Enfortumab + Pembro in cis-ineligible MIBC followed by postOP EV + Pembro based off #KEYNOTE905 #EV303 study: - EF…
0
2
0
In our “Challenging Cases” 🗣️ on non-muscle invasive bladder cancer w/ @shilpaonc & @JoshMeeks we touched on: ✅ BCG, BCG + IO, IO alone ✅ MultiD/MedOnc role early on Full discussion: ⭐️ https://t.co/sY7M5MgZRG ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates
1
11
28
Here is the #UromigosLive video for EVP in MIBC & IMVIGOR11 with ctDNA and atezolizumab 👉
1
16
44
🚨Uromigos Live 2025! In this exciting session Brian takes the role of the FDA and we conduct a mock Oncologic Drugs Advisory Committee on the CREST and POTOMAC data. Don't miss it! 🍎 Apple Podcasts: https://t.co/hH6nixdPuw 🎧Spotify: https://t.co/dxACkcyJDF 🎙️ GU Oncology
0
6
11
Stimulating discussion👉rapidly evolving 1st line systemic treatment options of metastatic UC #bladdercancer in #uromigoslive @Uromigos global meeting, Nashville👉List of novel agents is striking👇@OncoAlert @BladderCancerUS
Grand start of #UromigosLive @Uromigos by @brian_rini @tompowles1 👉major emphasis on early career investigators👇wonderful to have @huntsmancancer fellow @ziremozay win the only golden ticket award👉it’s a global level meeting now👇kudos to the team👏👏@OncoAlert
0
19
35
Please consider supporting @neerajaiims for @ASCO nominating commmitee. I can’t think of finer physician scientist to represent us. @SWOG @huntsmancancer @AmerUrological @UroOnc.
0
0
5
Dear Colleagues, A Reminder that the ASCO Elections are OPEN and you can cast your vote Now🗳️ 👉 https://t.co/33BWZoiipL ⭐️The Network would like to Congratulate one of Our Founding Faculty🚨 @neerajaiims 🇺🇸of @HuntsmanCancer & @UUtah on being a candidate for the nominating
0
16
30
Important new data from @EliLillyandCo presented at @AACR @theNCI @EORTC 2025 👉 independent validation of heterogeneous membranous NECTIN-4 expression in UC! NECTIN-4 was only detected in 113/176 EV-naïve UC specimens (primary + metastatic), app. 1/3 is NECTIN-4 negative.
5
24
52
Mock ODAC on the CREST and POTOMAC trials from #UromigosLive 2025. See the slides below to follow along with the discussion. Did our panel vote for or against approval? https://t.co/mzMt6lcIv7
0
26
41
The first session from #UromigosLive 2025 is available! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the neoadjuvant EVP and other data. @OncoAlert
https://t.co/3rJI1srhuI
spotifycreators-web.app.link
The first session from UromigosLive 2025! In this episode, Tom moderates as Jonathan Rosenberg, Matt Galsky, Kala Sridhar and Josh Meeks discuss the peri-operative space and the impact of the...
1
9
16
These remarkable data (📈 pCR rates with EV-P) raise the question: how will we apply and personalize local consolidation, surgery or radiation? When should we do it and for which patients? @tompowles1 @ChadTangMD @leslieballas @drjefstathiou @JoshMeeks @PGrivasMDPhD @koshkin85
0
8
15
Team America 🇺🇸 🇨🇦 have their educational video - with novel soundtrack - for Uromigos cup 🏆. Eurasia is winning. ♥️ =points. Surely it’s time for a win for the Americas. #UromigosLive @OncoAlert @montypal
2
36
76
#UromigosLive DV + Toripalimab vs EV + Pembro: diseccionando las diferencias entre los dos esquemas con una gran mesa dirigida por @tompowles1 con @shilpaonc, @MichvdHeijden, Dr. Galsky y Dr. Juo @OncoAlert @OncoReporte @Uromigos @tompowles1 @PGrivasMDPhD @joshmeeks @montypal
0
8
12
Uromigos #UromigosLive 2025 kicking off! Starting with an All Star ⭐️ #bladdercancer panel. @Uromigos @brian_rini @tompowles1 @DrRosenbergMSK @JoshMeeks @kalasri3 Matt Galsky @BladderCancerUS
1
10
22
#UromigosLive Segunda mesa del día: ADCs en cáncer de vejiga 💥 🗣️Chair: @tompowles1 👥Ponentes: Jun Guo MD, @MichvdHeijden, Matt Galsky MD, @shilpaonc 1️⃣¿Cuándo interrumpir DV + toripalimab? 2️⃣¿Sabemos suficiente sobre HER2 como biomarcador? 3️⃣¿Cuál es el alcance global de
0
6
10
#UromigosLive Seguimos con la mesa de tratamiento perioperatorio en MIBC. 📌 Ahora el debate se centra en el manejo de preservación vesical. Algunas preguntas que nuestros ponentes están abordando: 💭 ¿Podremos evitar la cirugía en pacientes seleccionados? 🔬 ¿Qué ensayo
0
6
9